Dyne Therapeutics (DYN) Capital Expenditures (2019 - 2026)

Dyne Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $77000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 165.52% year-over-year to $77000.0; the TTM figure through Mar 2026 stood at $18.8 million (up 750.86% YoY), while the FY2025 annual figure was $18.8 million, up 690.82% from the prior year.
• Capital Expenditures was $77000.0 for Q1 2026 at Dyne Therapeutics, down from $18.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $18.4 million in Q3 2025 to a low of -$1.7 million in Q3 2022.
• Historically, Capital Expenditures has averaged $1.4 million across 5 years, with a median of $126000.0 in 2022.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures slumped 183.62% in 2022, then surged 38287.5% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $85000.0 in 2022, then surged by 725.88% to $702000.0 in 2023, then soared by 231.62% to $2.3 million in 2024, then soared by 691.49% to $18.4 million in 2025, then slumped by 99.58% to $77000.0 in 2026.
• The last three Capital Expenditures figures came in at $77000.0 (Q1 2026), $18.4 million (Q3 2025), and $335000.0 (Q2 2025), per Business Quant data.